RESTENOSIS AFTER CORONARY ANGIOPLASTY - VALUE OF EXPERIMENTAL-MODELS

被引:0
|
作者
BAUTERS, C [1 ]
HAMON, M [1 ]
VANBELLE, E [1 ]
DUPUIS, B [1 ]
LABLANCHE, JM [1 ]
BERTRAND, ME [1 ]
机构
[1] FAC MED LILLE, SERV PHARMACOL, F-59045 LILLE, FRANCE
关键词
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Restenosis is the main complication of coronary angioplasty. Many experimental models have been developed over the last few years, reflecting very active research work in this field. The value of exprimental models may be discussed under two headings : improvement in our understanding of the mechanisms of restenosis and the development of preventing strategies. The smooth muscle cell is the main cause of restenosis, experimental models having demonstrated a triple response which has been observed clinically : proliferation, migration to the intima and synthesis of the extracellular matrix. The mechanisms controlling this response are not fully understood, the most likely candidates being desendethelialisation, platelets and other circulating components of the blood, vasopressive hormones especially the renin-angiotensin system, growth factors and finally the degree of direct trauma to the smooth muscle cells. Experimental models also allow evaluation of therapeutic strategies elaborated to reduce the frequency of restenosis in clinical practice : three strategies are identifiable : systemic treatment , local treatment and genetic therapy. At the present time, none of these approaches has been clearly shown to be effective clinically though some positive results have been observed in the animal.
引用
收藏
页码:47 / 56
页数:10
相关论文
共 50 条
  • [41] FOSINOPRIL SODIUM IN RESTENOSIS PREVENTION AFTER CORONARY ANGIOPLASTY
    DESMET, WJ
    VROLIX, MC
    DESCHEERDER, IK
    VANLIERDE, JM
    PIESSENS, JH
    CIRCULATION, 1992, 86 (04) : 54 - 54
  • [42] FIBRINOGEN AFTER CORONARY ANGIOPLASTY AS A RISK FACTOR FOR RESTENOSIS
    MONTALESCOT, G
    ANKRI, A
    VICAUT, E
    DROBINSKI, G
    GROSGOGEAT, Y
    THOMAS, D
    CIRCULATION, 1995, 92 (01) : 31 - 38
  • [43] RESTENOSIS AFTER SUCCESSFUL PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY
    KLEIN, LW
    ROSENBLUM, J
    PROGRESS IN CARDIOVASCULAR DISEASES, 1990, 32 (05) : 365 - 382
  • [44] Impact of restenosis 10 years after coronary angioplasty
    Espinola-Klein, C
    Rupprecht, HJ
    Erbel, R
    Nafe, B
    Brennecke, R
    Meyer, J
    EUROPEAN HEART JOURNAL, 1998, 19 (07) : 1047 - 1053
  • [45] Pharmacological approaches to the prevention of restenosis after coronary angioplasty
    Hamon, M
    Lecluse, E
    Monassier, JP
    Grollier, G
    Potier, JC
    DRUGS & AGING, 1998, 13 (04) : 291 - 301
  • [47] PREVENTION OF RESTENOSIS BY LOVASTATIN AFTER SUCCESSFUL CORONARY ANGIOPLASTY
    SAHNI, R
    MANIET, AR
    VOCI, G
    BANKA, VS
    AMERICAN HEART JOURNAL, 1991, 121 (06) : 1600 - 1608
  • [48] Probucol and multivitamins in the prevention of restenosis after coronary angioplasty
    Lisi, DM
    NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (26): : 1919 - 1919
  • [49] Predictors for restenosis after angioplasty of chronic coronary occlusions
    Sirnes, PA
    Molstad, P
    Myreng, Y
    Golf, S
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 1998, 67 (02) : 111 - 118
  • [50] INEFFECTIVENESS OF COLCHICINE FOR THE PREVENTION OF RESTENOSIS AFTER CORONARY ANGIOPLASTY
    OKEEFE, JH
    MCCALLISTER, BD
    BATEMAN, TM
    KUHNLEIN, DL
    LIGON, RW
    HARTZLER, GO
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1992, 19 (07) : 1597 - 1600